Press Releases

Press Releases

Press Releases

April 6, 2016
CAMBRIDGE, Mass., April 6, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced that management will present a
March 31, 2016
CAMBRIDGE, Mass., March 31, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, recognizes World Lipodystrophy Day and has partnered with
March 4, 2016
CAMBRIDGE, Mass., March 4, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced that management will present a
January 19, 2016
Appointment adds depth in clinical and regulatory leadership CAMBRIDGE, Mass., Jan. 19, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases,
November 8, 2015
Webcast to review data scheduled for Sunday, November 8 at 1:00 p.m. Eastern Time CARLSBAD, Calif., and CAMBRIDGE, Mass., Nov. 8, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), and its subsidiary, Akcea Therapeutics, today announced positive results from a
November 5, 2015
Trial marks second study for volanesorsen in a rare, genetic lipid disorder CARLSBAD, Calif., and CAMBRIDGE, Mass., Nov. 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) and its wholly owned subsidiary, Akcea Therapeutics, today announced the start of a Phase 3 study to evaluate
July 29, 2015
Publication highlights the therapeutic potential of volanesorsen to address unmet needs in patients with high apoC-III and triglyceride levels CARLSBAD, Calif. and CAMBRIDGE, Mass. , July 29, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics,
July 22, 2015
Publication highlights importance of Lp(a) as a risk factor for cardiovascular disease and the therapeutic potential of antisense drugs CARLSBAD, Calif. and CAMBRIDGE, Mass. , July 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea
July 6, 2015
BOSTON , July 6, 2015 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIII Rx ) for the treatment of patients with
May 28, 2015
CARLSBAD, Calif. , May 28, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:    Akcea Therapeutics Webcast When:    Thursday, June 4 at 1:00 p.m. ET / 10:00 a.m.